<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364956">
  <stage>Registered</stage>
  <submitdate>4/12/2013</submitdate>
  <approvaldate>9/12/2013</approvaldate>
  <actrnumber>ACTRN12613001340729</actrnumber>
  <trial_identification>
    <studytitle>Comparison of two doses of citrate in regional citrate anticoagulation during hemodialysis</studytitle>
    <scientifictitle>Comparison of biocompatibility markers with two doses of citrate in regional citrate anticoagulation during hemodialysis</scientifictitle>
    <utrn>U1111-1148-0399</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hemodialysis
</healthcondition>
    <healthcondition>kidney disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single, 4 hour hemodialysis with regional citrate anticoagulation with citrate dose 55 mmol/h</interventions>
    <comparator>Single, 4 hour hemodialysis with regional citrate anticoagulation with citrate dose 37,5 mmol/h</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Increase in thrombin-antitrombin complex (TAT, human ELISA kit), normalised to hematocrit before dialysis</outcome>
      <timepoint>during 4 hour dialysis</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in complement fragment C5a (human ELISA kit), normalised to hematocrit before dialysis</outcome>
      <timepoint>after 30 minutes of dialysis</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>increase in plasma platelet factor 4 (PF4), normalised to hematocrit before dialysis</outcome>
      <timepoint>during 4 hour dialysis</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>increase in plasma myeloperoxidaze (MPO), normalised to hematocrit before dialysis</outcome>
      <timepoint>during 4 hour dialysis</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>pre-filter ionized calcium, measured with ion-selective electrode ionometer</outcome>
      <timepoint>30 minutes and 240 minutes after starting hemodialysis</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>adult patients, needing hemodialysis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>acute illness, acute bleeding, known malignancy, current infection, immunosuppressive or anticoagulant therapy, known intolerance to citrate anticoagulation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation not concealed</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>University Medical Center Ljubljana</primarysponsorname>
    <primarysponsoraddress>Zaloska 7
1000 Ljubljana</primarysponsoraddress>
    <primarysponsorcountry>Slovenia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Javna agencija za raziskovallno dejavnost RS</fundingname>
      <fundingaddress>Bleiweisova cesta 30
1000 Ljubljana</fundingaddress>
      <fundingcountry>Slovenia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To compare markers of biocompatibility with two different doses of citrate in hemodialysis with regional citrate anticoagulation</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National medical ethics committee</ethicname>
      <ethicaddress>prof. Joze Trontelj
Inst. za klinicno nevrofiziologijo
UKC LJubljana
Zaloska 7
1000 LJubljana</ethicaddress>
      <ethicapprovaldate>19/03/2013</ethicapprovaldate>
      <hrec>89/03/13</hrec>
      <ethicsubmitdate>4/03/2013</ethicsubmitdate>
      <ethiccountry>Slovenia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jakob Gubensek</name>
      <address>University Medical Center Ljubljana
Dept. of nephrology
Zaloska 7
1000 Ljubljana</address>
      <phone>+386 1 522 3112</phone>
      <fax />
      <email>jakob.gubensek@kclj.si</email>
      <country>Slovenia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jakob Gubensek</name>
      <address>University Medical Center Ljubljana
Dept. of nephrology
Zaloska 7
1000 Ljubljana</address>
      <phone>+386 1 522 3112</phone>
      <fax />
      <email>jakob.gubensek@kclj.si</email>
      <country>Slovenia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jakob Gubensek</name>
      <address>University Medical Center Ljubljana
Dept. of nephrology
Zaloska 7
1000 Ljubljana</address>
      <phone>+386 1 522 3112</phone>
      <fax />
      <email>jakob.gubensek@kclj.si</email>
      <country>Slovenia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>